Summit Therapeutics Inc. Increase (Decrease) in Accrued Liabilities
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Accrued Liabilities of $32.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-07-23
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $20.74M, a 328.36% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $12.22M, a 658.41% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $5.53M, a 142.78% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $945.00K, a 83.97% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $12.93M, a 8.85% increase from fiscal 2024.
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $11.88M.
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$2.38M, a 149.71% decline from fiscal 2022.
- Summit Therapeutics Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $4.78M, a 5.77% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 11 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $32.95M 10-Q · filed 2026-07-23 | $38.49M derived: sum of 3 quarters · filed 2026-07-23 | $39.43M derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2026-03-31 | $12.22M 10-Q · filed 2026-04-30 | $17.75M derived: sum of 2 quarters · filed 2026-04-30 | $18.70M derived: sum of 3 quarters · filed 2026-04-30 | $23.54M derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-12-31 | $5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $6.48M derived: sum of 2 quarters · filed 2026-02-23 | $11.32M derived: sum of 3 quarters · filed 2026-07-23 | $12.93M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $945.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $5.79M derived: sum of 2 quarters · filed 2026-07-23 | $7.40M 10-Q · filed 2025-10-20 | $9.68M derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-06-30 | $4.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $6.45M 10-Q · filed 2026-07-23 | $8.73M derived: sum of 3 quarters · filed 2026-07-23 | $14.63M derived: sum of 4 quarters · filed 2026-07-23 | ||||
| 2025-03-31 | $1.61M 10-Q · filed 2026-04-30 | $3.89M derived: sum of 2 quarters · filed 2026-04-30 | $9.78M derived: sum of 3 quarters · filed 2026-04-30 | $15.72M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.17M derived: sum of 2 quarters · filed 2026-02-23 | $14.11M derived: sum of 3 quarters · filed 2026-02-23 | $11.88M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $5.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $11.83M derived: sum of 2 quarters · filed 2025-10-20 | $9.60M 10-Q · filed 2025-10-20 | $9.89M 10-Q · filed 2024-10-30 | $14.95M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | $5.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $3.71M 10-Q · filed 2025-08-11 | $3.80M 10-Q · filed 2024-08-06 | $9.06M derived: sum of 3 quarters · filed 2026-02-23 | $8.86M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | -$2.23M 10-Q · filed 2025-05-01 | -$2.15M 10-Q · filed 2024-05-01 | $3.12M derived: sum of 2 quarters · filed 2026-02-23 | $2.92M derived: sum of 3 quarters · filed 2026-02-23 | -$5.33M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $5.15M derived: sum of 2 quarters · filed 2026-02-23 | -$3.11M derived: sum of 3 quarters · filed 2026-02-23 | -$2.38M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$8.46M derived: sum of 2 quarters · filed 2024-10-30 | -$7.73M 10-Q · filed 2024-10-30 | -$7.76M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2023-06-30 | -$8.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$7.53M 10-Q · filed 2024-08-06 | -$7.56M derived: sum of 3 quarters · filed 2025-02-24 | -$1.67M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2023-03-31 | $730.00K 10-Q · filed 2024-05-01 | $695.00K derived: sum of 2 quarters · filed 2025-02-24 | $6.59M derived: sum of 3 quarters · filed 2025-02-24 | $6.34M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2022-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $5.86M derived: sum of 2 quarters · filed 2025-02-24 | $5.61M derived: sum of 3 quarters · filed 2025-02-24 | $4.78M 10-K · filed 2025-02-24 | ||||
| 2022-09-30 | $5.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.65M derived: sum of 2 quarters · filed 2023-11-07 | $4.82M 10-Q · filed 2023-11-07 | $6.58M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.08M 10-Q · filed 2023-08-09 | $684.00K derived: sum of 3 quarters · filed 2023-08-09 | $267.00K derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | -$832.00K 10-Q · filed 2023-05-11 | $930.00K derived: sum of 2 quarters · filed 2023-05-11 | $513.00K derived: sum of 3 quarters · filed 2023-05-11 | $2.28M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.34M derived: sum of 2 quarters · filed 2023-03-09 | $3.11M derived: sum of 3 quarters · filed 2023-03-09 | $5.08M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | -$417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.35M derived: sum of 2 quarters · filed 2022-11-09 | $3.31M 10-Q · filed 2022-11-09 | $4.41M 10-Q · filed 2021-11-15 | $3.21M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.73M 10-Q · filed 2022-08-11 | $3.28M 10-Q · filed 2021-08-12 | $3.63M derived: sum of 3 quarters · filed 2022-08-11 | $2.98M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $1.96M 10-Q · filed 2022-05-11 | $2.10M 10-Q · filed 2021-05-17 | $1.86M derived: sum of 2 quarters · filed 2022-05-11 | $1.21M derived: sum of 3 quarters · filed 2022-05-11 | $1.41M derived: sum of 4 quarters · filed 2022-05-11 | |||
| 2020-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$748.00K derived: sum of 2 quarters · filed 2021-11-15 | -$551.00K derived: sum of 3 quarters · filed 2021-11-15 | -$1.30M 10-K · filed 2021-03-31 | ||||
| 2020-09-30 | -$648.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$451.00K derived: sum of 2 quarters · filed 2021-11-15 | -$1.20M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$548.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$745.00K 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | -$51.00K 10-K · filed 2021-03-31 | |||||||
| 2019-09-30 | -$556.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$244.00K 10-Q · filed 2020-11-16 | ||||||
| 2019-06-30 | $312.00K 8-K · filed 2020-09-29 | |||||||
| 2019-01-31 | $144.00K 10-K · filed 2021-03-31 | |||||||
| 2018-01-31 | $1.84M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |